乌龙制药 URGN 深 沪
等待开盘 09-18 09:30:00 美东时间
18.10
+0.030
+0.17%
华盛通- 最 高18.65
- 今 开18.16
- 成交量 135.55万股
- 最 低 17.9401
- 昨 收 18.07
- 总市值 8.35亿
- 52周最高 21.71
- 市盈率 静 --
- 换手率 2.94%
- 52周最低 3.42
- 委 比 -99.93%
- 总股本 4610.75万
- 历史最高 69.568
- 量 比 1.10
- 振 幅 3.93%
- 历史最低 3.42
- 每 手 1
- 风险率 1.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. announced the grant of inducement restricted stock units (RSUs) to 40 new employees, as an incentive for their employment. These RSUs, totaling up to 67,700 ordinary shares, will vest equally over three years. The RSUs are subject to UroGen’s 2019 Inducement Plan and were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The new team members will support the commercialization of Jelmyto and ZUSDURI and the development ...
09-08 12:00
UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma Ltd. announced its participation in three investor conferences in September: the Wells Fargo Healthcare Conference on September 3rd, the Cantor Fitzgerald Global Healthcare Conference on September 4th, and the H.C. Wainwright 27th Annual Global Healthcare Conference on September 8th. All events will be conducted as Fireside Chats and webcasts will be available on the company’s Investor Relations website, with replays accessible for ...
08-21 12:00
Piper Sandler Initiates Coverage On UroGen Pharma with Overweight Rating, Announces Price Target of $36
Piper Sandler analyst Kelsey Goodwin initiates coverage on UroGen Pharma (NASDAQ:URGN) with a Overweight rating and announces Price Target of $36.
08-19 20:04
Cardinal Health周四盘前下跌 19亿美元收购交易致股价下挫
美东时间周三08：48，Cardinal Health（CAH）股价下跌0.2%。该公司周三宣布以19亿美元收购医疗技术公司UroGen Pharma（U...
08-14 20:50
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
UroGen Pharma Announces 24-Month DOR Of 72.2% By Kaplan-Meier Estimate In Patients Who Achieved CR At Three Months From Phase 3 ENVISION Trial Of ZUSDURI For Intravesical Solution
24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%)PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma
08-05 20:07
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
UroGen Pharma Ltd. will report its second quarter 2025 financial results on August 7, 2025, followed by a live webcast and conference call at 10:00 AM ET. The webcast will be available on UroGen’s Investor Relations website, with a replay accessible for 30 days. UroGen specializes in developing innovative treatments for urothelial and specialty cancers using its RTGel reverse-thermal hydrogel technology.
07-29 12:00
UroGen Pharma Announces Publication In Reviews In Urology Of Results From Phase 3b Study Evaluating Feasibility Of Administering ZUSDURI For Intravesical Solution In Home Setting
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, today announced the publication in Reviews in Urology of results
07-28 20:08
UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma announced the publication of results from a five-year long-term extension study of the Phase 2b OPTIMA II trial evaluating ZUSDURI (mitomycin) for intravesical solution in patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The study demonstrated durable, long-term complete responses (CRs) in patients who achieved initial CR with ZUSDURI. Among 17 patients entering long-term follow-up, the med...
07-21 12:00
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. announced the completion of patient enrollment in its Phase 3 UTOPIA clinical trial for UGN-103, a next-generation formulation of mitomycin for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The trial enrolled 99 patients globally and utilizes UroGen’s RTGel technology, offering potential improvements over ZUSDURI, including simplified manufacturing and reconstitution pr...
07-07 12:00
